CD200 Expression in Neuroendocrine Neoplasms.
| Autor: | Love JE; Western Washington Pathology, Tacoma., Thompson K; PhenoPath Laboratories, Seattle, WA., Kilgore MR; Department of Pathology., Westerhoff M; Department of Pathology., Murphy CE; Department of Pathology., Papanicolau-Sengos A; OmniSeq, Buffalo, NY., McCormick KA; Medical Oncology., Shankaran V; Medical Oncology., Vandeven N; Medicine and Dermatology., Miller F; MultiCare Health System, Tacoma, WA., Blom A; Medicine and Dermatology., Nghiem PT; Medicine and Dermatology., Kussick SJ; PhenoPath Laboratories, Seattle, WA.; Laboratory Medicine, University of Washington, Seattle. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | American journal of clinical pathology [Am J Clin Pathol] 2017 Sep 01; Vol. 148 (3), pp. 236-242. |
| DOI: | 10.1093/ajcp/aqx071 |
| Abstrakt: | Objectives: CD200 expression has been well studied in hematopoietic malignancies; however, CD200 expression has not been well-characterized in neuroendocrine neoplasms. We examined CD200 expression in 391 neuroendocrine neoplasms from various anatomic sites. Methods: Tissue blocks containing pulmonary small cell carcinoma, pulmonary carcinoid, large cell neuroendocrine carcinoma, pancreatic neuroendocrine tumor, gastrointestinal carcinoid, and Merkel cell carcinoma were evaluated for CD200 expression by immunohistochemistry. A set of nonneuroendocrine carcinomas was stained for comparison. Results: CD200 was expressed in 87% of the neuroendocrine neoplasms studied, including 60 of 72 (83%) pulmonary small cell carcinomas, 15 of 22 (68%) pulmonary carcinoids, three of four (75%) pulmonary large cell neuroendocrine carcinomas, 125 of 146 (86%) Merkel cell carcinomas, 79 of 83 (95%) gastrointestinal luminal carcinoids, and 56 of 60 (93%) pancreatic neuroendocrine tumors. Thirty-two of 157 (20%) nonneuroendocrine carcinomas expressed CD200. In gastrointestinal carcinoid and pancreatic neuroendocrine neoplasms, CD200 negativity correlated with higher grade. Conclusions: CD200 is a relatively sensitive marker of neuroendocrine neoplasms and represents a potential therapeutic target in these difficult-to-treat malignancies. (© American Society for Clinical Pathology, 2017) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|